1.10
-0.07(-5.98%)
Currency In USD
| Previous Close | 1.17 |
| Open | 1.15 |
| Day High | 1.15 |
| Day Low | 1.06 |
| 52-Week High | 10.13 |
| 52-Week Low | 1.06 |
| Volume | 163,618 |
| Average Volume | 78,598 |
| Market Cap | 24.62M |
| PE | 0.14 |
| EPS | 7.71 |
| Moving Average 50 Days | 1.47 |
| Moving Average 200 Days | 2.45 |
| Change | -0.07 |
If you invested $1000 in Boundless Bio, Inc. Common Stock (BOLD) since IPO date, it would be worth $72.7 as of June 01, 2025 at a share price of $1.1. Whereas If you bought $1000 worth of Boundless Bio, Inc. Common Stock (BOLD) shares 1 year ago, it would be worth $110M as of June 01, 2025 at a share price of $1.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Boundless Bio Announces Portfolio Prioritization and Runway Extension
GlobeNewswire Inc.
May 23, 2025 8:01 PM GMT
Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through expected proof-of-concept clin
Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire Inc.
May 09, 2025 11:00 AM GMT
Initial proof-of-concept data from the ongoing BBI-355 Phase 1/2 POTENTIATE trial in patients with oncogene-amplified cancers anticipated in the second half of 2025 Novel Kinesin program on track for mid-2025 development candidate nomination and IND
Boundless Bio to Participate in the Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Apr 03, 2025 11:00 AM GMT
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene am